Zepbound dosing schedule

Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist approved for chronic weight management. Like all medications in this class, it follows a structured dose titration schedule — starting low and increasing gradually over several months. This approach is not arbitrary. It is designed to give your body time to adjust and to minimize gastrointestinal side effects that are most common in the early weeks of treatment.

This guide walks through the complete Zepbound dosing schedule, what to expect at each stage, and the circumstances under which your clinician may modify the standard timeline.

Why titration matters

Tirzepatide works by activating two incretin hormone receptors — GIP and GLP-1 — which affect appetite signaling, gastric emptying, and insulin sensitivity. These are powerful physiological changes, and starting at a full therapeutic dose would overwhelm most patients’ systems.

Gradual dose increases serve three purposes:

• Minimizing GI side effects. Nausea, vomiting, diarrhea, and constipation are the most common side effects of tirzepatide. Starting low and increasing slowly gives your GI tract time to adapt to slower gastric emptying and changes in motility.
• Allowing your body to adjust. Your appetite regulation, blood sugar response, and satiety signals all shift as the medication takes effect. A gradual ramp allows these changes to occur in a controlled, tolerable way.
• Following clinical trial protocols. The Zepbound titration schedule is based on the SURMOUNT clinical trial program, which established the safety and efficacy of this specific dosing approach. Deviating from the protocol means moving outside of what has been studied.

The standard Zepbound schedule

The FDA-approved titration for Zepbound follows a step-wise increase every four weeks. Each dose level uses a specific injection pen, and each step lasts a minimum of four weeks before the next increase.

An important point many patients overlook: the maintenance dose is not automatically 15mg. Your clinician will determine your maintenance dose based on your individual response. The FDA-approved maintenance doses are 5mg, 10mg, and 15mg, though some clinicians may hold patients at intermediate doses (7.5mg or 12.5mg) based on individual response and tolerability. Some patients achieve their target weight loss at 5mg or 10mg and never need to increase further.

What to expect at each dose

Every patient responds differently, but there are general patterns that most patients experience as they move through the titration schedule.

2.5mg (Weeks 1–4)

This is a sub-therapeutic dose. Its primary purpose is to let your body acclimate to tirzepatide, not to produce significant weight loss. Most patients experience mild effects at this stage:

• Slight reduction in appetite, though many patients report minimal change
• Mild nausea in the first 1–2 days after injection, usually resolving quickly
• Some patients notice subtle changes in how food tastes or how quickly they feel satisfied
• Weight loss at this dose is typically minimal — do not be discouraged

5mg (Weeks 5–8)

This is where most patients begin to notice meaningful appetite changes. The medication starts to have a more noticeable effect on hunger and satiety:

• Reduced interest in eating between meals
• Earlier satiety — feeling full sooner during meals
• Some patients experience a reduction in food noise (the constant background thinking about food)
• GI side effects may increase temporarily during the first week at this dose

7.5mg (Weeks 9–12)

Appetite suppression becomes more pronounced. Many patients describe this as the dose where the medication begins to feel like it is working:

• Noticeable reduction in daily caloric intake without conscious restriction
• Stronger satiety signals — portions naturally decrease
• Weight loss typically becomes more consistent and measurable
• GI side effects from the dose increase usually resolve within 1–2 weeks

10mg (Weeks 13–16)

Significant appetite reduction and consistent weight loss are common at this dose. For some patients, this is the maintenance dose:

• Strong appetite suppression throughout the week
• Reduced cravings for high-calorie foods
• Measurable improvement in metabolic markers (blood sugar, triglycerides, blood pressure)
• If side effects are manageable and weight loss is on track, your clinician may recommend staying here

12.5mg–15mg (Week 17+)

These are the highest available doses. Not every patient needs to reach this level, but for those who do, the effects are typically at their maximum:

• Maximum appetite suppression
• Sustained, consistent weight loss
• Potential for the most pronounced GI side effects, though most patients who have titrated gradually tolerate these doses well
• Your clinician will determine whether 12.5mg or 15mg is appropriate based on your response at 10mg

When your clinician may slow down

The four-week intervals in the standard schedule are minimums, not requirements. Your clinician may extend any step by an additional four weeks (or longer) if you are experiencing side effects that have not resolved. Common reasons to slow the titration:

• Persistent nausea. If nausea has not improved after 2–3 weeks at a dose, increasing will likely make it worse. Staying at the current dose allows your body more time to adjust.
• Vomiting. Any vomiting that occurs more than occasionally warrants a conversation with your clinician about the pace of titration.
• Significant GI side effects. Severe diarrhea, constipation, or abdominal pain that interferes with daily life is a signal to pause before increasing.
• Dehydration risk. If GI symptoms are causing fluid loss or making it difficult to eat and drink adequately, stabilizing at the current dose is the safer approach.

When your clinician may stop at a lower dose

Not every patient needs to reach 12.5mg or 15mg. There are several valid reasons your clinician may recommend maintaining at a lower dose:

• Adequate weight loss at a lower dose. If you are achieving your target weight loss rate at 5mg or 10mg, there is no clinical reason to increase further. The goal is effective weight management, not reaching the highest dose.
• Intolerable side effects at higher doses. Some patients tolerate 7.5mg or 10mg well but experience significant GI side effects at higher doses. In these cases, the best maintenance dose is the highest dose you can tolerate comfortably.
• Cost or insurance considerations. All Zepbound dose strengths are priced similarly, but some insurance plans may have specific coverage criteria. Your clinician and care team can help you work through these considerations.
• Patient preference. Some patients prefer the side effect profile at a lower dose and are satisfied with a slower rate of weight loss. This is a legitimate clinical decision.

Your clinician will regularly assess whether your current dose is producing adequate results. If weight loss has plateaued and side effects are manageable, they may recommend increasing. If results are strong at a lower dose, staying there is often the right call.

Missed doses

Life happens, and missed doses are common. Knowing what to do when you miss one can prevent unnecessary anxiety and keep your treatment on track.

If you miss multiple doses in a row, contact your PEAK care team before resuming. Depending on how long the gap has been, your clinician may recommend restarting at a lower dose to re-acclimate your body, particularly if you have been off the medication for two or more weeks.

Switching from Wegovy to Zepbound

Some patients switch from Wegovy (semaglutide) to Zepbound (tirzepatide) due to improved insurance coverage, better tolerability, or a desire to try a different mechanism of action. This is a clinical decision that should always be made in consultation with your prescribing clinician.

A few important points about switching:

• Dose equivalency is not straightforward. Wegovy and Zepbound are different medications with different mechanisms. There is no direct mg-to-mg conversion. A patient on Wegovy 2.4mg does not automatically start Zepbound at the highest dose.
• Your clinician determines your starting dose. Based on your current Wegovy dose, your tolerability history, and your weight loss trajectory, your clinician will select an appropriate Zepbound starting dose. This may or may not be the 2.5mg starting dose.
• Expect a transition period. Even if you have been on a GLP-1 medication for months, switching to a dual-agonist means your body needs time to adjust to the GIP receptor activation. Some patients experience a recurrence of GI side effects during the switch.
• Timing the switch. Your clinician will advise on when to take your first Zepbound dose relative to your last Wegovy dose, accounting for the medications’ different half-lives and durations of action.

At PEAK, we build every patient’s titration plan individually. We monitor your progress at each dose level, adjust the pace based on how you are responding, and make sure you understand what to expect at every step. That is what clinician-led weight management looks like in practice.

Important safety information: Zepbound carries a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. It is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tirzepatide has also been associated with pancreatitis; discontinue promptly if pancreatitis is suspected and seek medical attention for severe abdominal pain that does not go away. Gallbladder-related events, including gallstones, have been reported, particularly with rapid weight loss. Discuss your full medical history with your clinician before starting treatment.

The PEAK Clinical Team

PEAK Wellness & Aesthetics

Evidence-based guidance from our board-certified clinicians specializing in medical weight loss and obesity medicine.